Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q3 2017 · 10-Q
Revenue$37.00K$37.00K−90.2% vs Q3 2016 Net Income-$3.91M-$3.91MN/M vs Q3 2016 EPS Diluted-$0.04-$0.04N/M vs Q3 2016 Operating Income-$3,936,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$3,831,000N/M Margins · derivedOperating margin-10637.8%−9827.3 pt vs Q3 2016
Net margin-10575.7%−9774.6 pt vs Q3 2016
ended Mar 31, 2017 · filed May 15, 2017 · 45 d after period end